In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Pfizer released positive top line results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide). 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
Cancer start-up Black Diamond Therapeutics has announced a significant restructuring as part of its plan to focus resources on its lead drug, BDTX-1535. 10 October 2024
The European Medicines Agency (EMA) has accepted for review the Marketing Authorization Applications for AVT03, a proposed biosimilar candidate to the Prolia and Xgeva (denosumab), submitted by Germany’s STADA Arzneimittel. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
Bayer has entered into a collaboration with MOMA Therapeutics to develop a small molecule oncology program using the latter’s proprietary KNOMATIC platform. 9 October 2024
Genor Biopharma has announced plans for a significant merger with Edding Group, marking one of the first reverse takeovers involving a Hong Kong-listed biopharma company. 8 October 2024
China-headquartered clinical-stage biotech MediLink Therapeutics has announced a global clinical trial collaboration and supply agreement with US major Amgen. 8 October 2024
Germany’s Eckert & Ziegler, a specialist in radioisotopes for medical, scientific and industrial applications, has announced a global clinical supply agreement with GlyTherix, an Australian targeted radiotherapy firm specializing in developing antibody radiopharmaceuticals for solid tumors. 8 October 2024
US clinical-stage biotech OnKure Therapeutics has announced the completion of its previously announced merger with Reneo Pharmaceuticals. 8 October 2024
Daejeon-based Orum Therapeutics, a specialist in degrader-antibody conjugates (DAC), has filed for an initial public offering (IPO) on South Korea's Kosdaq market. 7 October 2024
Mosaic Therapeutics, a UK-based oncology therapeutics company dedicated to resolving cancer’s complexity to power new combination therapies for patients, has announced the appointment of Barry Davies as chief scientific officer. 7 October 2024
Novartis this morning announced that it is broadening its portfolio of cancer immunotherapies with the acquisition of Admune Therapeutics and licensing agreements with Palobiofarma and XOMA Corp. 21 October 2015
The German Institute for Quality and Efficiency in Health Care (IQWiG) has examined in a dossier assessment whether US pharma major Bristol-Myers Squibb’s Opdivo (nivolumab) offers an added benefit over the appropriate comparator therapy for advanced melanoma. 20 October 2015
New data show that Japanese pharma major Eisai’s Lenvima (lenvatinib) improves progression-free survival for people with progressive radioiodine-refractory differentiated thyroid cancer (RR-DTC) regardless of metastatic site, with the exception of the brain. 20 October 2015
The Food and Drug Administration has granted Breakthrough Therapy designation for US pharma giant Pfizer’s once failed inotuzumab ozogamicin for the treatment of acute lymphoblastic leukemia (ALL). 20 October 2015
Danish biotech company Nuevolution has entered into a collaboration with Janssen Biotech, one of the Janssen Pharmaceutical companies of Johnson & Johnson. 19 October 2015
Athenex, until recently known as Kinex Pharmaceuticals, announced on Friday the completion and execution of a definitive agreement with the Banan District in Chongqing, China, to construct two separate pharmaceutical manufacturing plants on Banan sites. 19 October 2015
French biotech firm Oncodesign has announced the creation of a sales and marketing subsidiary based in Cambridge, Oncodesign Biotechnology, near Boston, USA, and the establishment of a joint venture, Synergie MTL, with Mispro Biotech Service, to develop a research facility in Montreal, Canada. 19 October 2015
Bristol-Myers Squibb has entered into an exclusive worldwide license and collaboration agreement for the development and commercialization of Five Prime Therapeutics’ colony stimulating factor 1 receptor (CSF1R) antibody program. 15 October 2015
Peregrine Pharmaceuticals says it has expanded its ongoing cancer immunotherapy clinical collaboration with AstraZeneca to include a second, later-stage trial. 15 October 2015
Janssen Biotech, a subsidiary of US health care giant Johnson & Johnson, today announced collaborations with two Canadian biotechnology companies, Toronto-based Novera Therapeutics and Montreal-based enGene. 14 October 2015
Contract development and manufacturing company ProBioGen and antibody therapeutics company Zymeworks have signed an agreement where ProBioGen will complete cell line development of a Zymeworks candidate. 14 October 2015
UK organization the Cell Therapy Catapult has signed an agreement with Asterias Biotherapeutics, engaging the Cell Therapy Catapult in advancing development of an Asterias product. 13 October 2015
Aeterna Zentaris on Tuesday said Data and Safety Monitoring Board (DSMB) has recommended the late stage trial for zoptarelin doxorubicin to treat advanced, recurrent or metastatic endometrial cancer, continue as planned. 13 October 2015
Boehringer Ingelheim and Swiss-Italian biotech firm Philogen plan to collaborate on investigating novel treatment approaches for acute myeloid leukemia (AML). 13 October 2015
Can-Fite BioPharma says that its oncology drug candidate, CF102, has been granted Orphan Drug designation by the European Medicines Agency for the indication of hepatocellular carcinoma. 12 October 2015
Eli Lilly and China’s Innovent Biologics have expanded their drug development collaboration, already one of the largest in China between a multi-national and domestic biopharmaceutical company. 12 October 2015
Anglo-Swedish drug major AstraZeneca has halted studies looking at the combination of two experimental drugs, AZD9291 and MEDI4736 (durvalumab) in advanced non-small cell lung cancer. 12 October 2015
New Phase III data has shown Halaven (eribulin) from Eisai can offer a significant overall survival benefit in rare soft tissue sarcomas compared to dacarbazine. 12 October 2015
The US Food and Drug Administration on Friday granted approved for pharma major Bristol-Myers Squibb’s Opdivo (nivolumab) injection, for intravenous use, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy. 10 October 2015